SecBot SecBot
PRESS-RELEASE ·Filed Aug 11, 2026

TARA

Protara Therapeutics
NEUTRAL
Impact 4/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor Q4 2026 for ADVANCED-2 enrollment completion and THRIVE-3 interim data, these are the next major catalysts. The ADVANCED-3 redesign suggests a broader but potentially slower NMIBC strategy; watch for protocol details. Cash runway into 2028 provides a long development horizon but no near-term revenue inflection.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.91
T+0 close · Aug 11, 2026 · via day close
Latest settled
−39.90%
T+60 · $2.35
Vs SPY
−39.41%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $3.91entry
  2. T+1 · 3mo ago −0.51%α −0.76% · $3.89
  3. T+5 · 3mo ago +1.79%α +2.19% · $3.98
  4. T+20 · 2mo ago −2.05%α −0.99% · $3.83
  5. T+60 · 13d ago −39.90%α −39.41% · $2.35
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Protara Therapeutics reported Q2 2026 net loss of $21.7M ($0.36/share), widening from a $15.0M loss in Q2 2025, driven by increased R&D spending. The company highlighted key pipeline milestones: expects to complete enrollment in the BCG-Unresponsive cohort of the ADVANCED-2 trial in Q4 2026, is redesigning the ADVANCED-3 trial as an exploratory study, and remains on track to report interim THRIVE-3 results in Q4 2026. Cash of $161.9M is expected to fund operations into 2028, but the widening losses and trial redesign signal a longer path to commercialization without near-term revenue catalysts.

Key Financial Metrics

EPS
−$0.36
est −$0.31 · -16.1%
Rating
in line

Key Facts

  • Q2 2026 net loss of $21.7M ($0.36/share) vs $15.0M ($0.35/share) in Q2 2025
  • Cash and investments of $161.9M as of June 30, 2026, expected to fund operations into 2028
  • Expects to complete enrollment in BCG-Unresponsive cohort of ADVANCED-2 trial in Q4 2026
  • Redesigning ADVANCED-3 trial as multi-cohort exploratory study in broader NMIBC population
  • On track to report interim THRIVE-3 results for IV Choline Chloride in Q4 2026
  • Plans to submit BLA for TARA-002 in Lymphatic Malformations in 2H 2027
  • R&D expenses increased to $17.0M from $10.8M year-over-year

Financial Impact

Net loss widened by $6.7M YoY to $21.7M; cash burn rate increased with R&D spend up 58%

net losscash positionR&D expenses

Risk Factors

  • Clinical trial delays or negative data from ADVANCED-2 or THRIVE-3
  • Cash burn rate increasing faster than expected could require dilutive financing
  • BLA submission for TARA-002 in LMs not expected until 2H 2027, limiting near-term catalysts

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3342659

Track record

13 reports on TARA

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +17.50% at T+60 after the May 26, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.52 Now $2.38 +5.56% settles Feb 12
  2. Nov 6, 202610d ago 8-K Neutral 4/10 No price data
  3. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $2.30 Now $2.38 +3.48% settles Feb 4
  4. Oct 15, 20264w ago Press Release Neutral 3/10 Entry $2.40 Now $2.38 −0.83% settles Jan 12
  5. Aug 11, 202613w ago 8-K Neutral 4/10 No price data
  6. Aug 11, 202613w ago Press Release Neutral 4/10 Viewing Entry $3.91 to $2.35 Now $2.38 −39.13% ▼ −39.90% −39.41% vs SPY
  7. Jun 29, 202620w ago 8-K Neutral 2/10 Entry $3.82 to $3.54 Now $2.38 −37.70% ▼ −7.33% −10.15% vs SPY
  8. May 26, 202625w ago EFFECT Bearish 5/10 Entry $4.80 to $3.96 Now $2.38 +50.42% ▲ +17.50% +20.22% vs SPY
  9. May 15, 202626w ago Press Release Bullish 7/10 Entry $5.10 to $3.91 Now $2.38 −53.33% ▼ −23.33% −27.85% vs SPY
  10. May 13, 202626w ago 8-K Neutral 4/10 No price data
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 11, 2026